% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wark:300142,
author = {A. Wark and L. Hüfner and E. Meixner and J. Oelmann and L.
König and S. Höne and K. Lindel and J. Debus$^*$ and N.
Arians},
title = {{C}linical {I}mpact of {MRI}-{G}uided
{I}ntracavitary-{I}nterstitial {B}rachytherapy in the
{C}urative {M}anagement of {A}dvanced-{S}tage {C}ervical
{C}ancer.},
journal = {Current oncology},
volume = {32},
number = {3},
issn = {1198-0052},
address = {Toronto, Ontario},
publisher = {Multimed},
reportid = {DKFZ-2025-00633},
pages = {136},
year = {2025},
abstract = {This study investigates the clinical efficacy of MRI-based
adaptive brachytherapy (IGABT) using combined intracavitary
and interstitial techniques in the curative treatment of
patients with advanced cervical cancer (LACC). A
retrospective analysis was conducted on 149 LACC patients
treated at a single center. The therapeutic protocol
included intensity-modulated external beam radiotherapy
(IMRT) and IGABT. Dosimetric parameters were evaluated for
relevance for local control (LC), progression-free survival
(PFS), and overall survival (OS) using Kaplan-Meier
estimation, Cox regression, and log-rank test. Patients
predominantly presented with stage III/IV tumors $(81\%,$
FIGO 2018). The median high-risk clinical target volume
(hrCTV) was 34 cm3, with a median $D90\%$ dose of 88.9
GyEQD2. At 24 months, OS, PFS, and LC rates were $86\%,$
$57\%,$ and $81\%,$ respectively. FIGO stage, tumor volume,
and histology were significant predictors of PFS. Higher
total hrCTV doses were strongly correlated with improved LC
and PFS, emphasizing the importance of precise dosimetric
optimization in IGABT and confirming the critical role of
IGABT in achieving very good LC rates for LACC. The reported
LC rates are comparable to landmark studies, such as
INTERLACE and KEYNOTE-A18. This study validates the
effectiveness of MRI-guided IGABT in enhancing local tumor
control in advanced-stage cervical cancer while providing
insights into the prognostic implications of dosimetric
parameters such as hrCTV and point A. Future research should
address the persistent challenge of distant metastases by
exploring the integration of novel systemic treatment
options.},
keywords = {Humans / Female / Uterine Cervical Neoplasms: radiotherapy
/ Brachytherapy: methods / Middle Aged / Adult / Magnetic
Resonance Imaging: methods / Aged / Retrospective Studies /
Aged, 80 and over / Neoplasm Staging / Radiotherapy,
Image-Guided: methods / MRI-guidance (Other) / advanced
cervical cancer (Other) / image-guided adaptive
brachytherapy (Other)},
cin = {E050 / HD01},
ddc = {610},
cid = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40136340},
pmc = {pmc:PMC11940836},
doi = {10.3390/curroncol32030136},
url = {https://inrepo02.dkfz.de/record/300142},
}